Second-generation Stent for Complex Procedures
demonstrates good results and receives CE mark
Second-generation Stent for Complex Procedures. Following excellent clinical trial outcomes, the Taxus Liberté paclitaxel-eluting coronary stent system has now been approved in Europe for treatment of total occlusion (TO) and in-stent restenosis (ISR) in patients with coronary artery disease, including acute myocardial infarction (AMI). This stent, which uses a modified cell design intended for drug delivery in larger vessels, will be available in a 4-mm diameter and seven different lengths.
Nine-month data from a global, multi-centre trial comparing the second-generation stent system with the Taxus Express and Express2 paclitaxel-eluting stent systems confirmed safety and efficacy and demonstrated the excellent deliverability of the new stent system, even for patients with more complex lesions. The study documented significantly shorter average procedure times of 47.8 minutes for Liberté stent compared to 53 minutes in the control group. Furthermore, the need to use additional stents due to procedural complications was reduced by nearly 50% in the Liberté stent patients. The study results also support safety, as demonstrated by low rates of major adverse cardiac events (MACE) and stent thrombosis.
Second-generation Stent for Complex Procedures
Boston Scientific Corp.
